Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,039

Document Document Title
WO/2019/175405A1
6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]...  
WO/2019/169815A1
A radioactive molecular probe and an application thereof in detection of intravital islets, its structure is: formula (I), wherein R 1 are halogen, saturated aliphatic hydrocarbon group, unsaturated aliphatic hydrocarbon group and aromat...  
WO/2019/166962A1
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...  
WO/2019/166537A1
The present invention describes novel chelators (multidentate ligands) and precompounds for complexation of radiometals and non-radioactive counterparts, for use in radiopharmacy. The invention includes a process and a kit involving such...  
WO/2019/165290A1
The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions. Formula (I).  
WO/2019/158634A1
The present invention relates to deuterated derivatives of 9-(2,5-difluorophenethyl)-4- ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one having pharmacological activity, to processes of preparation of such compounds, to pharmaceutic...  
WO/2019/152958A1
Provided herein are methods of fluorinating organic compounds. The electrochemical fluorination and radiofluorination of organic molecules using the cation pool technique is described, where the 18F and/or 19F-fluorine ions are added aft...  
WO/2018/093794A3
A microfluidic chip device for the purification of radiochemical compounds includes a chip having an injection channel and intersecting branch channels with a plurality of valves are located along the injection channel and branch channel...  
WO/2019/145292A1
The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies usin...  
WO/2019/145294A1
The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's ...  
WO/2019/104179A4
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.  
WO/2019/145955A1
The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.  
WO/2019/145291A1
The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and othe...  
WO/2019/135386A1
The present invention provides a novel deuterated phospholipid and a method for producing same. The synthetic deuterated phospholipid according to the present invention can be used to address problems in the field. Antiphospholipid antib...  
WO/2019/132117A1
The present invention provides a precursor compound for preparing a radioactive compound for efficiently imaging a heart, a radioactive compound prepared by using the precursor compound, and a use thereof as a contrast agent for PET imag...  
WO/2019/129310A1
Disclosed are a deuterated elagolix derivative, a pharmaceutical composition, and uses thereof. The structure of the deuterated elagolix derivative of the present invention is as shown in formula (X). The deuterated elagolix derivative a...  
WO/2019/131458A1
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...  
WO/2019/122255A1
The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known c...  
WO/2019/126704A1
The invention provides deuterium-enriched isoindolinonyl-azepanediones, deuterium- enriched oxoquinazolin-3(4H)-yl-azepanediones, related compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical comp...  
WO/2019/123409A1
Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ...  
WO/2019/109021A1
The disclosure provides processes for synthesizing compounds for use as CFTR modulators.  
WO/2019/105913A1
The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.  
WO/2019/104179A1
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.  
WO/2019/098291A1
This method uses a positron-emitting nuclide-labeled amino acid or a derivative thereof to synthesize a positron-emitting nuclide-labeled protein by means of a cell-free protein synthesis system. Said cell-free protein synthesis system i...  
WO/2019/075574A1
The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of β-glucocerebrosidase activity.  
WO/2019/073408A1
The invention provides an oral extended release formulation for the treatment of treatment- resistant depression, treatment-resistant anxiety, and phobia.  
WO/2019/071130A1
The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method thatcan be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodi...  
WO/2019/056251A1
The present invention relates to a group of isotope labeling reagents for amino/phenolic hydroxyl labeling, and a synthesis method therefor. In a synthesis process, a reagent (such as a homologue of 6-aminocaproic acid) carrying both ami...  
WO/2019/055358A1
The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III)...  
WO/2019/049918A1
The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkyl...  
WO/2019/025137A1
The present invention refers to a process for transition-meta!-assisted 18F- deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials; tolerance of moisture and ambient atmosphere, la...  
WO/2019/027059A1
The purpose of the present invention is to produce a radiolabeled aryl compound by a simple method in which labeling can be carried out in a short time in high radiochemical yield and which renders the radiolabeled aryl compound usable i...  
WO/2019/015690A1
A deuterated 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I or a pharmaceutically acceptable salt, isomer or a mixture thereof, solvate, polym...  
WO/2019/006078A1
Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.  
WO/2018/232777A1
A synthesis method for an aromatic compound containing a difluorodeuteromethoxy functional group or a difluorodeuterothio functional group. In the presence of an alkali, a difluorocarbene donor and Ar-(XH)n and heavy water undergo a reac...  
WO/2018/235535A1
Provided is a production method for a radiohalogen-labeled compound, the method comprising: a step in which a radiohalogen-labeled precursor compound (S-L) including a leaving group (L) capable of nucleophilic substitution with a radioha...  
WO/2018/213426A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH2OPO(OH)2. Also provided are pharmaceutical compositions comprising th...  
WO/2018/206728A1
The invention relates to the use of a precursor for the production of carbon-11-labelled amino acids or derivatives thereof. According to the invention, the precursor is a compound of formula I: (formula I), where R1 and R2 are selected ...  
WO/2018/189560A1
The invention relates to a process for post-preparation labelling of liposomal formulations with F (fluorine) isotope, wherein a) during the preparation of the liposomal formulation, a phospholipid derivative modified by terminal alkyne ...  
WO/2018/176253A1
Provided are a group of isotope labelling reagents for carboxyl labelling and a synthesis method therefor, wherein one end of the isotope labelling reagent is a primary amine and the other end is a trimethyl ammonium salt; and the primar...  
WO/2018/176512A1
The invention falls within the technical field of pharmaceutical compounds, and in particular relates to a deuterated palbociclib derivative, a preparation method and the use thereof. The deuterated palbociclib derivative has a structure...  
WO/2018/183406A1
Composition, manufactures, and methods of making and using them, illustratively a process including the steps of: changing density of a composition including a neutron absorbent, the absorbent having a neutron absorption cross section gr...  
WO/2018/171816A1
Disclosed in the present invention are a deuterated dipeptide boronic acid or an ester compound thereof, or a crystalline form, pharmaceutically acceptable hydrate or solvate thereof, the structure thereof being shown in formula (a), whe...  
WO/2018/172243A1
The present invention is directed towards isomerically pure 18F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle...  
WO/2018/168643A1
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...  
WO/2018/164043A1
Provided is a labeled precursor compound represented by formula (2). (In the formula, S represents a substrate, L represents a C1-6 linear alkyl group which may contain an ether group, R1 and R2 each independently represent a C1-30 linea...  
WO/2018/165185A1
Long-term and high-density energy sources are described that utilize radioisotope batteries that provide a tritium (3H)-based direct energy conversion system. The beta radiation source is a nitroxide compound with a synthetic yield near ...  
WO/2018/158137A1
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeledflutemetamol, which comprises: (a) a step ...  
WO/2018/153966A1
The present invention relates to novel compounds useful for visualizing cell sen es c en ce in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particul...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  

Matches 1 - 50 out of 2,039